KTKirill A. Turupaev

Kirill A. Turupaev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kirill A. Turupaev has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nirogacestat in treatment of patients with desmoid tumors. Literature review

    by K. A. Turupaev, Турупаев К. А., O. P. Grebennikova, Гребенникова О. П., M. D. Budurova, Будурова М. Д., D. D. Ladyko, Ладыко Д. Д., V. Y. Selchuk, Сельчук В. Ю.

    This literature review analyzes the role of the gamma-secretase inhibitor nirogacestat in treating patients with progressive desmoid tumors. The article systematizes data on the molecular mechanisms of the drug's action, stages of its clinical development, and the final results of the phase III DeFi trial, which formed the basis for nirogacestat's regulatory approval. It is shown that the drug significantly improves progression-free survival, increases objective response rate, and leads to clinically meaningful improvement in quality of life. The review discusses nirogacestat's safety profile in detail, highlighting a specific yet reversible adverse event – ovarian dysfunction. The analyzed data provide evidence for the efficacy and safety of nirogacestat, supporting its consideration as a new therapeutic option for patients with progressive desmoid fibromatosis.

  • Open Access

    Will darolutamide in double combination become the new standard of treatment for hormone-sensitive prostate cancer?

    by Mariya I. Volkova, K. A. Turupaev

    Darolutamide is a high-affinity second–generation antiandrogen, the effectiveness and favorable safety profile of which have been proven two phase III randomized clinical trials (RCTs) in metastatic hormone-sensitive prostate cancer (mHSPC) as part of a triple combination with docetaxel and androgen deprivation therapy (ADT) (ARASENS), as well as non-metastatic castration-resistant prostate cancer in the composition double combination with ADT (ARAMIS). Positive results have now become available from another phase III RCT ARANOTE, aimed at comparing the efficacy of the double combination of darolutamide with ADT and placebo with ADT in patients with mHSPC. Darolutamide significantly prolonged radiological progression-free survival, reducing the risk of radiological progression or death by 46 % compared with placebo (primary endpoint), also provided benefit of secondary study endpoints, including time to castration resistance and time to pain progression. The clinical benefit of darolutamide in primary and secondary points was realized regardless of the volume of metastatic load. Data on overall survival is immature. The incidence of adverse events was low and similar in the darolutamide and placebo groups, with a lower incidence of fatigue in the darolutamide group. The obtained data on the effectiveness of darolutamide with ADT in mHSPC are comparable with the results of similar studies of other second-generation antiandrogens enzalutamide (ARCHES phase III RCT) and apalutamide (TITAN phase III RCT). Potentially, the combination of ADT with darolutamide could claim a place in the list of standard treatment methods and expand therapeutic options for patients with mHSPC.

  • Endosalpingiosis of the bladder. Clinical observation and literature analysis

    by K. A. Turupaev, D. D. Ladyko, A. K. Tsutsaev, A. V. Klimov, K. M. Figurin, V. B. Matveev

    We present a rare clinical observation of histologically confirmed endosalpingiosis of the bladder in a female patient aged 44 years who underwent combination treatment. This observation is the 8th documented case of isolated endosalpingiosis of the bladder in the world. The article demonstrates the rarity of endosalpingiosis of the bladder, complexity of differential diagnosis of this disease, and the necessity of comprehensive examination with mandatory accurate tumor histogenesis prior to determination of treatment tactics in patients with bladder neoplasms.

  • Open Access

    Cabozantinib in the treatment of patients with advanced renal cell carcinoma: A review

    by Maria I. Volkova, Kirill A. Turupaev, Tatiana A. Nersesova, Kira Y. Zaslavskaya

    The treatment strategy for patients with locally advanced and disseminated renal cell carcinoma (RCC) has undergone significant changes over the past 10 years. The emergence of effective antitumor immune response checkpoint inhibitors and high-affinity multikinase inhibitors of the second generation, the introduction of prognostic factors to personalize treatment, as well as the optimization of the sequence and combinations of drug regimens, have significantly increased the survival rates of patients with advanced RCC. Cabozantinib is one of the high-affinity multikinase inhibitors of the second generation with proven antitumor activity and safety in patients with advanced RCC. The results of registration studies contributed to the introduction of cabozantinib, both as monotherapy and in combination with nivolumab, into international and Russian clinical guidelines for the treatment of RCC patients across a wide range of indications. The launch of Cabozantinib-Promomed on the Russian market expands access to this treatment option for patients with RCC. The article presents the results of clinical studies of cabozantinib in patients with locally advanced and disseminated RCC, as well as bioequivalence studies of Cabozantinib.

  • Open Access

    Renal cell carcinoma associated with von Hippel–Lindau syndrome: an ambispective study

    by Maria I. Volkova, Kirill A. Turupaev, Margarita G. Filippova, Daria D. Ladyko, Ogulshat R. Sinitsyna, Yana V. Gridneva, Vsevolod B. Matveev

    Background. Renal cell carcinoma (RCC) associated with von Hippel-Lindau syndrome (VHL) is characterized by multifocal bilateral involvement of the renal parenchyma and is the leading cause of death in this category of patients due to disease progression or the development of end-stage chronic kidney disease. Aim. To analyze the treatment outcomes of patients with RCC associated with VHL syndrome. Materials and methods. The ambispective study included data of 30 patients treated with VHL-associated RCC from 2016 to 2024. In 23 (76.7%) cases, VHL syndrome was classified as type 1, and in 7 (23.3%) as type 2B. Non-metastatic RCC at the initial diagnosis was detected in 28 (93.3%) patients and metastatic RCC in 2 (6.7%). Extrarenal manifestations of VHL syndrome occurred in all patients. Watchful waiting was used in 6 (20.0%) patients, surgical treatment of renal parenchyma tumors in 21 (70.0%), metastasectomy – in 2 (6.7%), and systemic antitumor therapy in 3 (10.0%). Treatment of extrarenal manifestations of VHL syndrome included surgical interventions in 20 (66.7%) patients, radiation therapy in 8 (26.7%), and laser therapy in 9 (30.0%). The median follow-up for all patients from the RCC detection was 46.6 [1-249.5] months. Results. The four-year overall (OS) and disease-specific (DSS) survival rates for all 30 patients were 93.3% and 93.3%, respectively. In 28 patients with primary non-metastatic RCC, the 4-year metastasis-free survival (MFS) was 74.2%. In 21 patients after radical surgery for the primary non-metastatic renal cell carcinoma, the 4-year OS was 88.9%, DSS was 88.9%, relapse-free survival (RFS) was 62.9%, local recurrence-free survival was 53.9%, and MFS was 63.6%. In patients with distant metastases, the 4-year OS was 66.7%. Two (6.7%) patients developed terminal chronic kidney disease requiring permanent hemodialysis. Conclusion. VHL-associated RCC is a chronic disease with a torpid course, allowing to recommend organ-sparing treatment of primary tumors and metastasis-directed therapy of oligometastases. Antiangiogenic therapy is effective in metastatic RCC.


  • Open Access

    Immediate and long-term outcomes of surgical treatment in patients with retroperitoneal and abdominal desmoid fibromatosis: A retrospective study

    by Kirill A. Turupaev, Marina D. Budurova, Maxim P. Nikulin

    Background. The main method of treatment of desmoid fibromatosis is surgical, especially in patients with symptomatic disease or in cases of progression during the Look and Stay period. Due to the rarity of the disease, different localization, unpredictability of the clinical course, the lack of generally accepted clear criteria for choosing a treatment method and/or a sequence of treatment methods, the determination of prognostic criteria for the course of the disease is of great scientific and practical interest. Aim. To study the immediate and long-term outcomes of surgical treatment in patients with retroperitoneal and abdominal desmoid fibromatosis. Materials and methods. The study analyzed the data of 121 patients with histologically verified retroperitoneal and abdominal desmoid fibromatosis who underwent surgical treatment at the Blokhin National Medical Research Center of Oncology from 1999 to 2022. Results. In 89% of cases, desmoid tumors are resectable; however, resections of adjacent organs are often required to remove the tumor mass completely. The frequency of combined interventions in the abdominal and retroperitoneal groups was 7.0 and 60.4%, respectively. Tumor cells along the edge of the incision are identified in 15.8% of patients, including 10% of patients with macroscopically detectable residual tumors. Surgical treatment of patients with desmoid tumors is associated with an acceptable complication rate and provides high rates of overall and relapse-free survival. Risk factors for disease-free survival of operated patients are retroperitoneal localization, multicentric tumor growth, and R2 category. Conclusion. The treatment of patients with retroperitoneal and abdominal desmoid tumors should be carried out in specialized clinics with sufficient experience in performing surgical interventions, including combined ones. The treatment approach in patients with desmoid tumors should be selected by a multidisciplinary team based on personalized oncological and functional prognoses in accordance with the prognostic risk groups.


  • Open Access

    Organ-preserving surgical treatment of a patient with synchronous bilateral morphologically different renal cell carcinoma, inferior vena cava tumor thrombus and pyeloureteral segment stone: clinical case

    by K. A. Turupaev, A. V. Klimov, O. A. Khalmurzaev, G. A. Arakelyan, D. D. Ladyko, S. D. Bezhanova, V. O. Vorob’eVa, A. V. Smirnova, V. B. Matveev

    Kidney cancer is the 3rd most common disease in oncological urology. In 4–10 % cases, tumor thrombus of the inferior vena cava is diagnosed. In literature, single-digit number of cases of organ-preserving surgical treatment of patients with kidney cancer complicated by tumor thrombus is described. The article presents a rare clinical case of synchronous bilateral morphologically different kidney cancer with tumor thrombus in the left renal vein, perirenal segment of the inferior vena cava, pyeloureteral segment stone in the right ureter.

  • Solitary metastasis of clear cell renal cell carcinoma in the small intestine 10 years after right nephrectomy

    by Budurova, N.V. Vorobyov, S.I. Poluektov, V.S. Surkova, N.A. Grishin, K.A. Turupaev, M.A. Chernichenko, A.B. Ryabov

    Kidney cancer is one of the most common urological oncological diseases. In 20—25% of patients after radical surgical treatment, metachronous metastases develop. With the emergence of new drug treatment strategies, there has been an increase in overall survival in patients with progressive renal cell carcinoma (RCC). As a result, the rare localization of metastasis, such as RCC metastases in the small intestine, is now more common than previously thought, and the number of published reports of RCC metastasizing to the small intestine has increased. This article presents a rare clinical observation of solitary metastasis of clear cell RCC in the small intestine complicated by recurrent small intestinal bleeding.

  • Open Access

    Opportunities and Role of the Multifunctional Simulation and Training Accreditation Center of the N. N. Blokhin National Medical Research Center of Oncology in the Training of Oncological Specialists

    by Михаил Евгеньевич Тимофеев, K. A. Turupaev, M. N. Kovaleva, O. A. Egenov, A. M. Galustov

    This paper presents the experience of a multifunctional simulation and training accreditation center of the N. N. Blokhin National Medical Research Center of Oncology of the training of oncological specialists in the Russian Federation.

  • Open Access

    Molecular-genetic landscape of abdominal and retroperitoneal desmoid fibromatosis: a retrospective study

    by Kirill A. Turupaev, Marina D. Budurova, Margarita G. Filippova, Artur A. Isayev, Yana V. Gridneva, Darya N. Khmelkova, Margarita A. Gayryan, Irina V. Mironova, Maxim P. Nikulin, Alena I. Puchkova, et al.

    Background. Desmoid fibromatosis (DF) is a rare mesenchymal tumor with invasive growth, a high relapse rate, and low incidence (24 cases per 1 million people per year). Given the small number of patients with DF and, as a result, the lack of knowledge of this disease, the search for molecular predictors of the disease course and the individualization of treatment and prevention is relevant. Aim. To study tumor cells' molecular genetic and immunohistochemical profile and determine their clinical significance in patients with abdominal and retroperitoneal DF. Materials and methods. A comprehensive analysis of clinical and laboratory data of 31 patients with abdominal and retroperitoneal DF, a molecular genetic and morphological study of tumor samples was performed, including next-generation sequencing (NGS) using the Onconetix oncology panel and an immunohistochemical study using antibodies to -catenin and estrogen and progesterone receptors. Results. NGS testing showed somatic mutations in 28 (90%) of the 31 tumor samples. Somatic mutations in the CTNNB1 gene were detected in 26 (84%) tumor samples: 21 (68%) patients had c.121AG (p.Thr41Ala, rs121913412), 3 (10%) patients had c.134CT (p.Ser45Phe, rs121913409), 1 (3%) patient had c.133TC (p.Ser45Pro, rs121913407), and 1 (3%) patient had c.122CT (p.Thr41Ile, rs121913413). Two (6%) patients had mutations in the APC gene: c.4381GT (p.Glu1461Ter, COSM30779) and c.4634CA (p.Ser1545Ter, rs863225356). In 3 (9%) patients, no mutations were detected in the studied genes. The immunohistochemical study showed the expression of -catenin in the cytoplasm and nuclei of tumor cells in 16 (51.6%) samples. Nuclear expression of estrogen and progesterone receptors was detected in 6 (19%) and 1 (3.2%) samples, respectively. Of 10 patients with established relapses, sequencing (NGS) showed a c.121AG mutation (p.Thr41Ala, rs121913412) in 7; 1 patient had a c.134CT mutation (p.Ser45Phe, rs121913409), and 2 patients had no mutations in tumor samples. Conclusion. The combination of factors such as the retroperitoneal DF, the presence of the c.121AG mutation (p.Thr41Ala, rs121913412) in the CTNNB1 gene, female gender, and young age, can warrant assigning the patient to the group with an unfavorable DF prognosis.